New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
08:33 EDTSRPTSarepta price target raised to $55 from $35 at RW Baird
Baird raised its price target on Sarepta following yesterday's bullish feedback from the FDA. The firm sees several scenarios that could lead to a favorable regulatory path including the validation of a controlled confirmatory study, guidance on moving forward in additional exons, and a determination the company can file for a new drug application this year. Shares are Outperform rated.
News For SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SRPT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use